Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection.

JL Platt, GM Vercellotti, BJ Lindman… - The Journal of …, 1990 - rupress.org
JL Platt, GM Vercellotti, BJ Lindman, TR Oegema Jr, FH Bach, AP Dalmasso
The Journal of experimental medicine, 1990rupress.org
Heparan sulfate proteoglycan associated with endothelial cells in normal blood vessels
inhibits intravascular coagulation and egress of blood cells and plasma proteins, key
features of hyperacute rejection. It was shown herein that exposure of cultured porcine
endothelium to human serum as a source of natural antibodies and complement caused
cleavage and release of 5% of endothelial cell proteoglycans within 4 min and greater than
50% within 1 h. Proteoglycan release depended on activation of the classical complement …
Heparan sulfate proteoglycan associated with endothelial cells in normal blood vessels inhibits intravascular coagulation and egress of blood cells and plasma proteins, key features of hyperacute rejection. It was shown herein that exposure of cultured porcine endothelium to human serum as a source of natural antibodies and complement caused cleavage and release of 5% of endothelial cell proteoglycans within 4 min and greater than 50% within 1 h. Proteoglycan release depended on activation of the classical complement pathway and preceded irreversible cell injury. These findings suggest that loss of endothelial cell proteoglycan may be a critical step in the pathogenesis of hyperacute rejection and in diseases involving humoral injury to endothelial cells.
rupress.org